NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
January 04 2022 - 6:50AM
Business Wire
Company to provide details on expansion
strategy
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
pharmaceutical company focused on developing and commercializing
scientifically formulated and clinically proven consumer products
for the eyecare and skincare markets, announces that management
will present a company overview at the H.C. Wainwright BioConnect
Virtual Conference being held January 10-13, 2022. A webcast of the
NovaBay presentation will be available on the Events page of the
company website beginning Monday, January 10, 2022 at 7:00 a.m.
Eastern time.
“Our acquisition of DERMAdoctor in November 2021 has created an
entirely new company with a dramatically accelerated growth
trajectory. We expect sales in 2022 to double from 2021 with a
considerably more rapid path to profitability,” said Justin Hall,
NovaBay’s CEO. “We’ve had significant success in transitioning
Avenova® from prescription-only to over-the-counter sales and are
eager to bring that expertise to all existing DERMAdoctor products.
Most importantly, expect to leverage DERMAdoctor’s deep expertise
in new product development to introduce both new DERMAdoctor and
Avenova products, with at least four new products launching in the
first half of 2022. I invite you to listen in to hear more details
on our plans for significant expansion.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. In November
2021, NovaBay acquired DERMAdoctor, LLC, a company offering more
than 30 dermatologist-developed skincare products sold through
traditional domestic retailers, digital beauty channels and
international distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
potential future product offerings, as well as generally the
Company’s expected future financial results. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute
to such differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the integration of DERMAdoctor’s business into the
Company’s business, the possibility that the available market for
the Company’s products will not be as large as expected, the
Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005430/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024